SGLT2 inhibitor: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 33: | Line 33: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Mechanism of action .png|SGLT2 inhibitor | |||
File:Phlorhizin.svg|Phlorhizin | |||
File:Dapagliflozin structure.svg|Dapagliflozin | |||
File:Empagliflozin.svg|Empagliflozin | |||
File:Canagliflozin.svg|Canagliflozin | |||
</gallery> | |||
Latest revision as of 01:14, 20 February 2025
SGLT2 inhibitors or Sodium-glucose co-transporter-2 inhibitors are a class of medications used primarily in the treatment of type 2 diabetes. They work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose in urine.
Mechanism of Action[edit]
SGLT2 inhibitors work by blocking the sodium-glucose co-transporter-2 (SGLT2), which is responsible for the majority of glucose reabsorption by the kidneys. By inhibiting this transporter, these medications increase the amount of glucose excreted in the urine, thereby lowering blood glucose levels.
Uses[edit]
SGLT2 inhibitors are primarily used in the treatment of type 2 diabetes. They may also be used in the management of heart failure and chronic kidney disease.
Side Effects[edit]
Common side effects of SGLT2 inhibitors include urinary tract infections, yeast infections, and increased urination. Rare but serious side effects may include ketoacidosis and kidney injury.
Examples[edit]
Examples of SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin.
